Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Timm Medical Broadens Incontinence Portfolio With UroSurge Acquisition

This article was originally published in The Gray Sheet

Executive Summary

Timm Medical Technologies plans to proceed with clinical trials of UroSurge's implantable SANS stoller afferent nerve stimulation device for treatment of urinary incontinence if its acquisition of UroSurge closes May 31 as planned. Financial terms of the deal were not disclosed.

You may also be interested in...

Medtronic Building InterStim Registry; Data Show Early Treatment Benefit

Medtronic is assembling a patient registry for the InterStim urinary incontinence sacral nerve stimulation device that will offer insight into current best practices for device application and quality of life.

UroSurge Urinary Incontinence Device To Hit U.S. Market In Next 2 Weeks

UroSurge says it will launch the Percutaneous Stoller Afferent Nerve Stimulation (SANS) system in the next two weeks for symptomatic treatment of urinary urgency, frequency or urge incontinence. FDA cleared the device Feb. 9 via a de novo 510(k) with clinical trials as a special control.

QUOTED. 3 April 2020. Minetta Liu.

Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts